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ABSTRACT
The celiac disease is an autoimmune gastrointestinal disorder caused by gluten from wheat, rye or barley. 
In genetically predisposed persons, gluten induces the immune-mediated inflammation of small intestinal 
mucosa. Histological lesions include intraepithelial lymphocytosis, crypt hypertrophy and villous atrophy, 
resulting in malabsorption of micro- and macronutrients. The only treatment for celiac patients is a permanent 
gluten-free diet (GFD). Reactive oxygen species (ROS) and oxidative stress are strongly associated with the 
celiac disease. Glutathione (GSH) is a main detoxifier of endogenous and exogenous ROS in the intestine. 
In order to explain the role of glutathione redox cycle in celiac patients, we examined the activities of GSH-
related antioxidant (AO) enzymes glutathione peroxidase (GPx) and glutathione reductase (GR), as well as 
the concentration of GSH in small intestinal biopsies and peripheral blood of children affected by the celiac 
disease. The concentration of lipid hydroperoxides (LOOH) as markers of oxidative damage was measured 
in the same samples. The results clearly demonstrate a significant malfunction of GSH redox cycle with a 
concomitant decrease in the capacity to regenerate GSH and detoxify LOOH in celiac patients, even after 
several years of GFD. The oral administration of GSH and a diet rich in natural antioxidants, as well as 
appropriate dietary supplements, could be of great benefit to the patients.
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INTRODUCTION
Glutathione is a powerful antioxidant, antitoxin 
and enzyme-cofactor. It often reaches millimolar 
concentrations in the cell, which makes it one 
of the most important intracellular antioxidants 
(Masella et al. 2005). Glutathione is mostly present 
in cells in a reduced form (GSH). In a healthy cell, 
oxidized glutathione (glutathione disulfide, GSSG) 
rarely overcomes 10 % of total glutathione pool 
(Kosower and Kosower 1978) and decreased GSH/
GSSG ratio is a good indication of oxidative stress 
(Hwang et al. 1992). GSH has a multiple function 
in the organism. GSH S-transferases (GST) use 
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it as a cofactor in the detoxification of various 
endogenous and exogenous toxins. Gamma-
glutamyl transpeptidase uses GSH as a cofactor 
in transporting amino acids into cells. A group of 
enzymes known as GSH transhydrogenases uses 
GSH in a wide range of –S-S- to –S-H conversions. 
GSH also has an indispensable role in the AO 
defense. GSH redox cycle is a crucial protective 
mechanism against cell membrane damage by 
lipid peroxidation (LPO), a chain reaction in which 
polyunsaturated fatty acids (PUFA) in membrane 
lipids are being oxidized by ROS (Spiteller 2007, 
Liu et al. 2005). The antioxidant enzyme GPx 
uses GSH for reducing LOOH and hydrogen 
peroxide (H2O2), while GR reduces GSSG with a 
simultaneous oxidation of nicotinamide adenine 
dinucleotide phosphate (NADPH). In addition 
to be a cofactor for GPx, GSH can directly react 
with free radicals and has an important role in 
regenerating active forms of other antioxidants due 
to its reduction potential.
The celiac disease is an autoimmune gastroin-
testinal disorder provoked by wheat gluten and 
related cereal proteins (from rye, barley and 
possibly oats). In genetically predisposed persons, 
gluten induces the immune-mediated inflammation 
of small intestinal mucosa. Histological lesions 
include intraepithelial lymphocytosis, crypt hyper tro-
phy and villous atrophy, resulting in an inadequate 
absorption of micro- and macronutrients from the 
intestinal tract. The clinical presentation of the 
celiac disease is exceedingly heterogeneous and 
varies greatly with the age of the patients, duration 
and intensity of the disease and possible presence of 
extra intestinal disorders (Esteve et al. 2006). The 
classical gastrointestinal form of the disease, which 
is present mostly in infants and young children, is 
characterized by diarrhea, flatulence and abdominal 
pain, failure to thrive or weight loss (Fasano and 
Catassi 2005). In older children and adults, a 
variety of other clinical manifestations has been 
described, including the atypical or asymptomatic 
form (Dewar and Ciclitira 2005, Farrell and Kelly 
2002, Murray 1999). The untreated celiac disease 
is associated with increased morbidity including 
various malignancies (Green et al. 2003). The only 
treatment for celiac patients is a permanent GFD, 
which usually rapidly solves gastrointestinal symp-
toms, while mucosal healing may prolong for months 
or years, especially in adult patients (Ryan and 
Kelleher 2000). GFD also prevents complications 
associated with the untreated celiac disease.
The activation of an immune cascade by gluten 
peptides leading to the inflammation of the intestinal 
mucosa is the main pathway of the pathogenesis of 
the celiac disease. However, direct cytotoxic effects 
of gluten should not be neglected. Several studies 
have shown that ROS and oxidative stress are 
strongly associated with the celiac disease (Dugas et 
al. 2003, Maiuri et al. 2003). In our previous papers 
we investigated the AO status of children affected 
by the celiac disease (Stojiljković et al. 2007, 2009). 
Since GSH is a main detoxifier of endogenous 
and exogenous ROS in intestine (LeGrand and 
Aw 2001), in this study we focused on the role of 
glutathione redox cycle in celiac patients.
MATERIALS AND METHODS
SUBJECTS
The study involved small intestinal biopsy speci-
mens and peripheral blood samples from 33 
children (19 girls and 14 boys; median age of 8 
years; range of 1-15 years) affected by the celiac 
disease. The diagnosis of the disease was made 
at the University Children’s Hospital, Belgrade, 
Serbia, according to the criteria of the European 
Society for Paediatric Gastroenterology, Hepatology 
and Nutrition (ESPGHN) (Walker-Smith 1990). 
Twenty children were diagnosed at the time of 
the investigation. All these children were making 
a gluten containing diet and had symptoms that 
are characteristic for the celiac disease, while the 
analysis of intestinal biopsy specimens revealed 
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a typical villous atrophy (active group). In 13 
children the diagnosis was made in early childhood 
and since then they have been subjected to GFD. 
At the time of sampling they were using GFD for 
2-5 years, and the histopathologic examination 
of their intestinal biopsies showed a completely 
healed mucosa (GFD group). In addition, blood 
and intestinal biopsy samples from 29 children with 
various gastrointestinal symptoms (fatigue, chronic 
abdominal pain, diarrhea and weight loss), but with 
normal endoscopic, histopathologic and serologic 
results, were used as a control group.
The investigation has been approved by the 
Ethical Committee of the School of Medicine, Univer-
sity of Belgrade. The parents of all patients included 
in the study provided a written informed consent.
SAMPLE PREPARATION
From each patient, 6-8 proximal small intestinal 
biopsy specimens, as well as peripheral blood 
samples, were obtained. Some of the biopsies were 
used for histopathological analysis, while others 
were washed in ice-cold saline and frozen at -70 °C 
for GPx, GR, GSH and LOOH assays. One biopsy 
specimen from each patient was kept on -70 °C 
for the GSH assay, while others were thawed 
within a week and homogenized in 20 volumes 
of cold sucrose buffer pH 7.4. Homogenates were 
vortexed 3 times for 15 seconds and then kept at 
-70 °C. Thawed homogenates were centrifuged 
(Eppendorf centrifuge 5417R, Eppendorf - Netheler 
- Hinz GmbH, Hamburg, Germany) at 8600 g, 4 °C 
for 10 minutes. Supernatants were stored at -70 °C.
The blood samples were collected in the 
morning, in tubes containing lithium heparin as the 
anticoagulant. For the GPx, GR and LOOH assay, 
the blood was centrifuged at 1000 g, 4 °C for 15 
minutes. The plasma was stored at -70 °C for the 
LOOH assay, and the buffy coat was discarded. 
The red blood cells were washed three times in cold 
saline and then lysed in 20 packed-cell volumes of 
ice-cold water. Lysates were centrifuged at 8500 g, 
4 °C for 10 minutes to remove the blood cell stroma, 
and supernatants were stored at -70 °C. For the GSH 
assay, the whole blood was frozen at -70 °C.
ASSAYS
All assays were performed spectrophotometrically 
(Perkin Elmer Spectrophotometer, Lambda 25, 
Perkin Elmer Instruments, Norwalk, CT, USA). The 
specific enzyme activities of GPx and GR in blood 
were expressed as units per gram of hemoglobin 
(U/g Hb), and in the intestinal mucosa as milliunits 
per milligram of protein (mU/mg). Concentrations 
of GSH and LOOH were expressed in micromoles 
per liter (µmol/L).
GPx assay. The GPx activity was determined 
by the Oxis Bioxytech® GPx-340™ Assay (Oxis 
Inter national, Inc., Portland, OR, USA). Upon the 
reduction of organic peroxide by GPx, GSSG is 
produced and its recycling to GSH by GR is accom-
panied by the oxidation of NADPH to NADP +. The 
rate of NADPH oxidation, followed by a decrease 
in absorbance at 340 nm as a function of time, is 
directly proportional to the GPx activity in the 
sample. One GPx-340 activity unit is defined as 1 
µmol of NADPH consumed per minute under the 
assay conditions.
GR assay. The activity of GR was measured 
by the Oxis Bioxytech® GR-340™ Assay (Oxis 
International, Inc., Portland, OR, USA). The assay 
is based on the oxidation of NADPH to NADP+ by 
GR from the sample. The rate of NADPH oxidation 
was determined by the rate of the decrease in 
absorbance at 340 nm. One GR-340 unit is defined 
as 1 µmol of NADPH oxidized per minute under 
the assay conditions.
GSH assay. The concentration of GSH was deter-
mined by the Oxis Bioxytech® GSH-420™ Assay 
(Oxis International, Inc., Portland, OR, USA). For 
the GSH assay in intestinal biopsy samples, the 
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thawed tissue was homogenized in 20 volumes 
of precipitating reagent (trichloroacetic acid), and 
homogenates were centrifuged at 3.000 g, 4 °C for 10 
minutes. Supernatants were used for the assay. For the 
GSH assay in blood, the thawed blood was vortexed 
with three volumes of precipitating reagent at 10.000 
g, room temperature, for 5 min, and supernatants 
were used for the assay. The method is based on the 
formation of a chromophoric thione. The reaction 
is performed in three steps. The sample was first 
buffered and treated with a reducing agent (tris 
(2-carboxyethyl)phosphine) to reduce any oxidized 
glutathione present in the sample. Then the chromogen 
(4-chloro-1-methyl-7-trifluoromethylquinolinium 
methylsulphate) was added, forming thioethers with 
all thiols in the sample. After the addition of a base to 
raise the pH over 13, a β-elimination specific to the 
GSH-thioether results in the chromophoric thione. 
The absorbance at 420 nm is directly proportional to 
the GSH concentration.
LOOH assay. The concentration of LOOH was 
determined by the Oxis Bioxytech® LPO-560™ 
Assay (Oxis International, Inc., Portland, OR, 
USA). The assay is based on the oxidation of 
ferrous to ferric ions by LOOH from the sample 
under acidic conditions. Ferric ions bind with the 
indicator dye (xylenol orange), forming a stable 
coloured complex. The absorbance at 560 nm is 
directly proportional to the LOOH concentration. 
To eliminate the H2O2 interference, the samples 
were pre-treated with catalase.
STATISTICS
Differences among the groups were tested by 
analysis of variance. Comparisons among the 
patient groups were performed by Bonferroni post 
hoc test. Correlations among AO enzyme activities, 
GSH concentration and LOOH concentration 
were evaluated by Pearson’s product moment 
correlation. A P value lower than 0.05 was 
considered significant.
RESULTS
The activities of GPx and GR and the concentrations 
of GSH and LOOH in small intestinal mucosa (left) 
and peripheral blood (right) are represented in 
Fig. 1. The GPx activity varied significantly among 
the examined groups, both in mucosa (F = 6.41, 
P < 0.01) and erythrocytes (F = 15.21, P < 0.001). 
In the active group the GPx activity in the mucosa 
was reduced for 30 % when compared to the control 
group (P < 0.01). The decrease in the GPx activity 
was found in erythrocytes as well, both in the active 
group, for about 35 % (P < 0.001), and the GFD 
group, for 20 % (P < 0.05).
Figure 1. The activities of glutathione peroxidase (GPx) and glutathione 
reductase (GR) and the concentrations of glutathione (GSH) and lipid 
hydroperoxides (LOOH) in small intestinal mucosa and peripheral blood 
of control subjects, patients on gluten-free diet (GFD) and patients with 
the active form of the celiac disease. *** P < 0.001, ** P < 0.01, 
* P < 0.05 significantly different from control subjects. ## P < 0.01 
significantly different from the GFD group.
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The GR activity varied significantly in the 
intestinal mucosa (F = 6.77, P < 0.01), but not in the 
erythrocytes (F = 1.86, P > 0.05). In comparison to the 
control group the GR activity decreased in the mucosa 
for about 30 % in active and GFD groups (P < 0.05).
A significant variance among the analyzed 
groups was found for the GSH concentration in 
the intestinal mucosa (F = 27.19, P < 0.001) and 
peripheral blood (F = 45.77, P < 0.001). In the mucosa 
of the active group, the GSH level was less than  50 
% of the control value (P < 0.001), while in the GFD 
group the decrease in the GSH concentration was 
more restrained (about 25 %, P < 0.05). The GSH 
concentration was also significantly reduced in the 
blood of active and GFD groups (~30 %, P < 0.001).
The levels of LOOH varied significantly in the 
intestinal mucosa (F = 11.30, P < 0.001) and in the 
plasma (F = 14.69, P < 0.001). The level of LOOH in 
the intestinal mucosa of celiac patients increased by 
40 % (P < 0.05) in the GFD and over 60 % (P < 0.001) 
in the active group in comparison to the control 
subjects. The increase in the LOOH level was also 
found in the patients’ plasma, but it was significant 
only in the active group (over 40 %, P < 0.001).
The correlations among the analyzed parameters 
are represented in Fig. 2. The GPx activity 
significantly correlated with the GSH concentration 
in small intestinal mucosa, as well as in blood. 
Significant negative correlations were found 
between GSH and LOOH concentrations both in 
intestinal mucosa and peripheral blood, while the 
GR activity negatively correlated with the LOOH 
concentration in the intestinal mucosa only. We 
also found significant positive correlations of all 
analyzed parameters in small intestinal mucosa and 
blood, with the exception of the GR activity (Fig. 3).
Figure 2. Data plot and coefficients of Pearson’s product moment correlation r between the GSH concentration and the GPx activitiy in small intestinal 
mucosa (a) and peripheral blood (b), the GSH concentration and the LOOH concentration in small intestinal mucosa (c) and peripheral blood (d), and 
the GR activity and the LOOH concentration in small intestinal mucosa (e) of control subjects, patients on gluten-free diet (GFD) and patients with 
the active form of the celiac disease.
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DISCUSSION
The intestinal mucosa is continually subjected to the 
influence of oxidants, mutagens and carcinogens 
from diet, as well as to endogenous ROS. Several 
defense mechanisms are implied in maintaining the 
cell integrity and tissue homeostasis: the intestine 
is able to retain high concentrations of antioxidants 
(GSH, vitamins E and C) and to up-regulate AO 
enzymes, while apoptosis is induced in spent or 
damaged enterocytes (Aw 1999). It was shown that 
xantine-oxidase (XO) is activated in the enterocytes 
of celiac patients, leading to the overproduction of 
free radicals and ROS (Boda et al. 1999). These 
pro-oxidant processes may cause further damage 
to the intestinal mucosa through free radical chain 
reaction in the LPO and elevated LOOH level, 
which can have far-reaching effects on the intestinal 
metabolic homeostasis. In our study, significantly 
increased concentrations of LOOH were found in 
the intestinal mucosa of patients with the active form 
of the disease, and even in patients on GFD. LOOH 
were also elevated in the plasma of celiac patients in 
the active group. Our results are in accordance with 
the findings of Rivabene et al. (1999) who reported 
an increased level of LOOH and a decreased level 
of GSH provoked by wheat gliadin in an in vitro 
study. The increased LPO of plasma chylomicrons 
and low-density lipoproteins of a celiac patient has 
also been reported (Lavy et al. 1993). It was shown 
that a high LOOH level provokes single- and 
double-strand DNA breaks as well as the oxidative 
damage of cell membranes (Wijeratne and Cuppett 
2006). Subtoxic concentrations of LOOH can cause 
an oxidative shift in the cellular redox status that 
is sufficient for an enhanced mitogenic response, 
while under a severe oxidative stress cells die by 
apoptosis or necrosis (Gotoh et al. 2002, Aw 1999). 
The GSH redox cycle is the principal mecha-
nism of detoxifying LOOH in the intestine (Aw 
2005). High levels of cell GSH are preserved by 
de novo synthesis, regeneration from GSSG, and 
in several cell types, including enterocytes, by 
an import via Na+-dependent transport system 
(Mårtensson et al. 1990). In our study, a significant 
decrease of the GSH concentration is found in the 
intestinal mucosa of celiac patients with the active 
form of the celiac diseas, and even in patients on 
the GFD regime the GSH level was 25 % less than 
in control subjects. The GSH concentration is also 
significantly reduced in the peripheral blood of both 
active and GFD patient groups. The GSH depletion 
is followed by a decrease of the GPx and GR 
activities. A reduced GPx activity has been found 
in biopsies and erythrocytes taken from celiac 
patients with severe villous atrophy (Ståhlberg et 
al. 1988, Ståhlberg and Hietanen 1991). Several 
in vitro studies have reported pro-oxidative 
effects of gliadin in human intestinal cell cultures 
(Dolfini 2002, Dolfini 2005). Rivabene et al. (1999) 
demonstrated that the antiproliferative effect of 
gliadin is associated with pro-oxidative changes, 
such as elevated LOOH level, reduced GSH 
level and progressive disappearance of sulfhydryl 
groups in proteins. The magnitude of these changes 
Figure 3. Data plot and coefficients of Pearson’s product moment 
correlation r among the GPx activitiy, GR activity, GSH concentration 
and LOOH concentration in small intestinal mucosa and peripheral 
blood of control subjects, patients on gluten-free diet (GFD) and 
patients with the active form of the celiac disease.
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correlated with the basal redox state of the cells, 
mainly the GSH content, suggesting that higher 
GSH levels could lessen cell susceptibility to 
gliadin. In another in vitro study, gliadin provoked 
a reduction in the GSH content and a gliadin 
concentration-related decrease in the activity of 
GR, GPx and GSH-S-transferase (Elli et al. 2003).
In our study the increased LOOH concentrations 
correlated with the reduction of the GSH content in 
the intestinal mucosa and peripheral blood. We also 
found a significant positive correlation between the 
GSH concentration and the GPx activity in both 
tissues, while the GR activity in the mucosa inversely 
correlated with the LOOH concentration. Since it 
was shown that GPx and GR are not influenced by 
a high LOOH concentration (Reddy and Tappel 
1974, Vilas et al. 1976), the decreased activities 
of these enzymes might be a consequence of the 
GSH depletion. Our results are consistent with the 
findings of Aw (1998) who demonstrated that the 
extent of LOOH catabolism and the kinetics of GPx 
and GR depend mainly on the availability of cell 
reductants (GSH and NADPH). Moreover, as Gpx 
is a selenium-dependent enzyme, a low Se level 
can also influence its activity. Selenium deficiency 
has already been reported in celiac patients (Stazi 
and Trinti 2010, Yuce et al. 2004). Previous studies 
have also shown a strong correlation between the 
Gpx activity and the Se level in blood, especially 
when the Se concentration is low (< 80 µg/L) 
(McKenzie et al. 1978, Lloyd et al. 1989).
Since sufficient GSH is essential for normal 
intestinal degradation of LOOH from diet, the 
reduced GSH level found in our study might promote 
their luminal retention and lymphatic transport. The 
LOOH challenge may provoke perturbation in the 
normal intestinal cell proliferation, differentiation 
and apoptotic responses, contributing to the increased 
risk of malignancy in untreated celiac patients.
Besides the GSH redox cycle, thioredoxin and 
a family of recently discovered peroxiredoxins are 
potent detoxifiers of peroxides. Thioredoxin and 
peroxiredoxins, by using redox-active cysteines 
rather than selenium, reduce hydrogen peroxide and 
organic peroxides. The active form of thioredoxin 
is recovered by selenoprotein thioredoxin reductase 
(Forman et al. 2002, 2004), while oxidized pero-
xiredoxins are reduced by thiols such as GSH, or 
ascorbic acid (Monteiro et al. 2007, Jönsson and 
Lowther 2007). Thioredoxin and peroxiredoxins 
have not been investigated in celiac disease yet. 
Still, the general absorptive dysfunction of small 
intestine in patients with the celiac disease could 
possibly diminish their peroxide detoxifying func-
tion via reduced level of selenium and GSH, as in a 
case of GPx recorded in this work.
Our results demonstrate that the oxidative stress 
is implicated in the pathology of celiac disease. 
The antioxidant capacity of celiac patients with the 
active form of the disease is significantly reduced 
by the GSH depletion and decreased activities of 
GSH-related enzymes in intestinal mucosa and 
peripheral blood. In patients on GFD, the pro-
oxidant/antioxidant balance is greatly recovered, but 
even in these patients the GSH levels in mucosa and 
peripheral blood, the GR activity in mucosa and the 
GPx activity in erythrocytes remain lowered, while 
LOOH are still elevated in mucosa. Interestingly, the 
GSH concentration in intestinal mucosa increased 
significantly in GFD patients when compared to the 
active group, while in blood it persists at very low 
levels. This could be explained by the fact that after 
the healing of intestinal mucosa and the regaining of 
its absorptive function, enterocytes are able to take 
dietary GSH from the intestinal lumen, which is an 
important source of intracellular GSH (Lash 1986, 
Mårtensson et al. 1990), while the rate of the GSH 
synthesis in the intestinal epithelial cells is relatively 
low (Williams and Aw 1994). The restoration of the 
GSH content in erythrocytes seems to be delayed 
and more complex, involving the transport of amino 
acids into cells and de novo intracellular synthesis. 
Cysteine is considered to be a rate-limiting amino 
acid for the GSH synthesis. It has been demonstrated 
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that the transport of cystine (an oxidized form of 
cysteine) is induced in erythrocytes under oxidative 
stress (Ohtsuka et al. 1988).
The pattern of the observed alterations in GSH 
redox cycle in the intestinal mucosa and peripheral 
blood is very similar, suggesting that these changes 
are of systemic character. Rivabene et al. (1999) 
proposed that a diffuse inflammatory process that 
is characteristic for the active phase of the celiac 
disease might represent a basis for the systemic 
disturbance of pro-oxidant/antioxidant balance in 
an organism. Significant positive correlations of 
all analyzed parameters except for the GR activity 
in the two tissues, observed in our study, strongly 
support this opinion.
Our results clearly demonstrate that the GSH 
concentration is severely reduced in small intestinal 
mucosa and blood of celiac patients, even after 
several years of GFD. It was shown that the oral 
administration of GSH increases its levels in small 
and large intestinal mucosa of mice and protects 
these tissues from cell degeneration induced by 
L-buthionine SR-sulfoximine (BSO), a specific 
inhibitor of the GSH synthesis (Mårtensson et al. 
1990). Considering a systemic decrease of the GSH 
level and overall AO capacity in celiac patients, 
the oral administration of GSH and a diet enriched 
by natural antioxidants and appropriate dietary 
supplements could be important for full healing of 
these patients. In addition, we suggest that nutritional 
evaluation confirming a 'replenishing of reserves' 
should be performed at the diagnosis level and at least 
once a year to address damage control in the patients.
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RESUMO
A doença celíaca é uma desordem gastrointestinal causada 
pelo glúten proveniente do trigo, centeio ou cevada. Em 
pessoas geneticamente predispostas, o glúten induz uma 
inflamação imune da mucosa do intestino delgado. As lesões 
histológicas incluem linfocitose intraepitelial, hipertrofia de 
criptas e atrofia vilosa, resultando em malabsorção de micro- 
e macronutrientes. O único tratamento para os pacientes 
celíacos é a restrição permanente de glúten na dieta (GFD).
Espécies reativas de oxigênio (ROS) e o estresse oxi-
dativo estão fortemente associados à doença celíaca. 
O glutatião (GSH) é o principal detoxificante de ROS 
endógeno ou exógeno no intestino. Para explicar o 
papel do ciclo redox do glutatião nos pacientes celíacos, 
nós examinamos as atividades das enzimas GSH-rela-
cionadas e anti-oxidantes (AO) glutatião peroxidase 
(GPx) e glutatião redutase (GR), assim como a concen-
tração de GHS em biópsias do intestino delgado e sangue 
periférico de crianças afetadas pela doença celíaca. A 
concentração dos hidroperóxidos lipídicos (LOOH) 
como marcadores do dano oxidativo foi medida em 
várias amostras.  Os resultados mostram claramente a 
mal função significante do ciclo redox do GSH com uma 
diminuição concomitante da capacidade de regenerar 
GSH e detoxificar LOOH nos pacientes celíacos, mesmo 
após vários anos de GFD. A administração oral de GSH 
e uma dieta rica em anti-oxidantes naturais, assim como 
de suplementos apropriados na dieta, poderiam ser de 
grande benefício aos pacientes.
Palavras-chave: enzimas anti-oxidantes, doença celíaca, 
glutatião, peroxidação de lipídios.
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